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Abstract
HER2 is a transmembrane receptor tyrosine kinase, which plays a key role in breast cancer
due to a common genomic amplification. It is used as a marker to stratify patients in the clinic
and is targeted by a number of drugs including Trastuzumab and Lapatinib. HER2 has previ-
ously been shown to translocate to the nucleus. In this study, we have explored the proper-
ties of nuclear HER2 by analysing the binding of this protein to the chromatin in two breast
cancer cell lines. We find genome-wide re-programming of HER2 binding after treatment
with the growth factor EGF and have identified a de novo motif at HER2 binding sites. Over
2,000 HER2 binding sites are found in both breast cancer cell lines after EGF treatment, and
according to pathway analysis, these binding sites were enriched near genes involved in pro-
tein kinase activity and signal transduction. HER2 was shown to co-localise at a small subset
of regions demarcated by H3K4me1, a hallmark of functional enhancer elements and HER2/
H3K4me1 co-bound regions were enriched near EGF regulated genes providing evidence
for their functional role as regulatory elements. A chromatin bound role for HER2 was verified
by independent methods, including Proximity Ligation Assay (PLA), which confirmed a close
association between HER2 and H3K4me1. Mass spectrometry analysis of the chromatin
bound HER2 complex identified EGFR and STAT3 as interacting partners in the nucleus.
These findings reveal a global role for HER2 as a chromatin-associated factor that binds to
enhancer elements to elicit direct gene expression events in breast cancer cells.
Introduction
Human epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth fac-
tor (EGF) family of receptor tyrosine kinases (ErbBs), which traditionally has been known as a
transmembrane tyrosine kinase receptor involved in signalling to the mitogen activated protein
kinase (MAPK) pathway and the phosphatidylinositol 3-kinase (PI3K) pathway. HER2 has no
known ligand but heterodimerises with other ErbB receptors when they are activated by ligand.
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HER2 is amplified in a number of breast cancer tumours, with the frequency reported to range
from 10% [1] to 30% [2]. Breast cancer patients with this amplification of HER2 have a signifi-
cantly poorer prognosis when compared to patients with non-amplified HER2 [2]. As a result
of its amplification and the location of HER2 in the extracellular membrane, a number of thera-
pies have been developed to target this molecule. The monoclonal antibody trastuzumab has
been used in the clinic to treat patients with HER2-positive breast cancer for a number of years
[3]. More recently, the small molecule tyrosine kinase inhibitor lapatinib, which targets both
HER2 and EGFR, and trastuzumab emtansine (TDM1), an antibody-drug conjugate, have
been introduced as a therapy for patients with metastatic breast cancer [4, 5].
The presence of HER2 in the nucleus was first noted by Xie and Hung [6], who also
reported that HER2 can function as a transcriptional activator. Giri et al [7] reported that
HER2 is transported to the nucleus by endocytosis, involving importin β1 and the nuclear
pore protein Nup358. Once in the nucleus, HER2 acts as a coactivator for signal transducer
and activator of transcription 3 (STAT3), in a complex alongside the progesterone receptor
(PR) and AP-1 [8–10]. These interactions were analysed via chromatin immunoprecipitation
(ChIP) at the cyclin D1 promoter in the mouse mammary C4HD cell line [8, 9] and at the
p21CIP1 promoter in the T47D human breast cancer cell line [10]. HER2 has also been
reported to bind to the COX-2 promoter in the breast cancer cell lines BT474 and SKBR3, and
the ovarian cancer cell line SKOV3 [11]. In metastatic breast cancer cell lines, Venturutti et al
[12] demonstrated that HER2 binds to the promoter region of a microRNA, in conjunction
with STAT3. In addition, Li et al [13] have reported that HER2 associates with β-actin and
RNA pol I, resulting in enhanced rRNA gene transcription. In the nucleus of a number of can-
cer cell lines, HER2 has been found to interact with macrohistone 2A1.2 [14]. Despite the fact
that a number of these publications show that the proportion of HER2 in the nucleus appears
to be quite low in comparison to that at the membrane, there appears to be an important role
for HER2 in the nucleus.
Further studies in clinical samples revealed the presence of nuclear HER2 (nHER2) in
tumours from breast cancer patients [15, 16]. Schillaci et al [16] reported nHER2 in 33.6% of
primary invasive breast carcinomas and this expression was a significant independent predic-
tor of worse overall survival in patients with membranous HER2 (mHER2). Dillon et al [15]
demonstrated an association between COX-2 expression and nHER2 in a large breast cancer
patient population, and nHER2 predicted poor disease-free survival in patients on endocrine
treatment. The role of nHER2 has recently been reported to be involved in resistance to trastu-
zumab, with nHER2 forming a complex at the DNA with STAT3 and ErbB3 [17].
These previous reports in cell lines and breast cancer samples indicate a role for nHER2 in
disease progression. However, the HER2-chromatin interactions have focused mainly on bind-
ing at specific loci of interest. We mapped nHER2 on a genome-wide scale for the first time,
using ChIP-exonuclease (ChIP-exo) [18], a high resolution transcription factor mapping pro-
tocol. We chose breast cancer cell lines with amplification of the ErbB2 locus which represent
different breast cancer subtypes, in order to analyse the importance of nHER2 in both of these
molecular environments. Using this approach, we sought to identify direct transcription target
genes of this important and complex factor.
Results
Global binding analysis of HER2 in SKBR3 cells reveals a de novo binding
motif
The association of the full-length transmembrane receptor HER2 with the DNA in breast can-
cer cells was first confirmed by chromatin fractionation and Western blotting. The cell lines
HER2 binding at the chromatin
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SKBR3 and BT474 which have an amplified ErbB2 locus were used in this project. In these two
breast cancer cell lines, HER2 was bound to the chromatin in both vehicle and EGF stimulated
conditions (S1A Fig), confirming previous findings showing that full-length HER2 can be
chromatin bound [6, 8–10]. Interestingly, ChIP-seq of HER2 in SKBR3 cells was not sensitive
enough to identify HER2 binding sites (S1B Fig) but the improved signal from ChIP-exo [18]
permitted global mapping. Cells were treated with EGF for three hours (S1C Fig) and HER2
ChIP-exo was conducted (Fig 1, S1D Fig), with peaks called using MACS [19]. In vehicle-
treated (asynchronous) and EGF-treated cells, 2,596 and 2,520 binding sites were identified
respectively but with only a small overlap (~15%) (Fig 1A and 1B). EGF treatment for 3 hours
induced binding at a number of new sites in the genome. In addition, the average binding
intensity increased in the presence of this growth factor, evident in the heatmap and in the cor-
responding average intensity plots (Fig 1A and 1B).
De novo motif analysis revealed a motif underlying the binding sites found in the EGF con-
dition and in the common sites bound in both treatment conditions (Fig 1C). This binding
site has no known corresponding transcription factor. The motif appears to be palindromic in
the core ’CGT_TGC’ sequence. Notably, this motif was not found in the SKBR3 asynchonous
only subset of binding sites. This finding, along with the low intensity of these binding sites
could indicate a lesser functional role of these binding sites. Analysis of the genes within 10 kb
of the binding sites revealed significant associations with genes in pathways involving signal
transduction and receptor/kinase activity (Fig 1D). Binding of HER2 was not found to be
enriched at any particular genomic feature such as promoters in comparison to the breakdown
of the whole genome into these features (S1E Fig).
EGF treatment induces increased binding in the BT474 breast cancer cell
line, with a considerable overlap with those found in the SKBR3 cell line
HER2 ChIP-exo was examined in another breast cancer cell line with an amplified ErbB2
locus, the BT474 cells. This cell line also expresses the progesterone receptor which has previ-
ously been reported to associate with HER2 at the chromatin [8–10]. HER2 peaks were evident
in both asynchronous and EGF-treated conditions (Fig 2A and 2B). The number of binding
sites of HER2 in the BT474 cell line increased considerably with treatment of EGF, however
the common sites found in both conditions had the strongest average intensity (Fig 2A & S2A
Fig). De novo motif analysis of the HER2 binding peaks revealed that all three subsets of bind-
ing peaks had a similar underlying motif to that found in the SKBR3 cells, implying a common
mechanism for HER2 chromatin binding (Fig 2C). Binding of HER2 in this cell line did not
show any enrichment to specific regions of the genome (S2B Fig). Interestingly, upon compar-
ison of the binding in the two breast cancer cell lines under un-treated conditions, (Fig 2D,
left) the majority of the peaks were unique to each cell line. In contrast, after treatment with
EGF (Fig 2D, right) the majority (85%) of the SKBR3 peaks were also found in the BT474 cell
line.
A subset of HER2 binding sites overlap with enhancer regions and are
found near genes involved in signalling pathways
Monomethylation of lysine 4 on histone 3 (H3K4me1) is enriched at enhancer regions in the
genome [20]. Given the fact that HER2 binding occurred throughout the genome, we hypothe-
sised that HER2 binding might occur at enhancers. H3K4me1 was mapped in EGF-treated
SKBR3 and BT474 breast cancer cell lines. Two replicates were performed for each cell line.
Comparison of the binding of this epigenetic mark with HER2 binding sites, revealed 413
common regions in the SKBR3 cell line, representing 16.4% of the HER2 peaks (Fig 3A). In
HER2 binding at the chromatin
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Fig 1. ChIP-exo reveals HER2 binding across the genome of the SKBR3 breast cancer cell line. Experiments were performed in asynchronous
conditions, with the supplementation of vehicle (H2O) or EGF (100ng/ul) for 3 hours. A) Venn diagram illustrating the overlap of peaks found in the
vehicle treated and EGF treated conditions and average intensity plots generated from the peaks within each subset. EGF treatment re-programmes
binding to new sites and increases the average intensity of binding. B) Heatmap illustrates the binding in the different subsets of peaks. C) De novo
motif analysis of the underlying DNA at the HER2 binding sites. A novel part-palindromic motif (CGT-TGC) was identified at the common binding
sites and those found after EGF treatment. D) Gene Ontology analysis of the genes found within 10kb of the binding sites were analysed using the Broad
Institute’s GSEA website. Signal transduction and receptor activity pathways feature in particular near the binding sites identified in EGF treated cells
SKBR3 cells.
https://doi.org/10.1371/journal.pone.0225180.g001
HER2 binding at the chromatin
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Fig 2. Binding analysis of HER2 in the BT474 cell line. Binding analysis of HER2 in the BT474 cell line reveals a considerable increase in binding after
EGF treatment, and shared a number of sites with the SKBR3 cell line. ChIPexo experiments were performed in asynchronous conditions, with the
supplementation of vehicle (H2O) or EGF (100ng/ul) for 3 hours. A) Venn diagram illustrating the overlap between the two treatment conditions in the
BT474 cell line. EGF treatment induces a considerable increase in binding sites. B) UCSC genome browser shots of unique and common sites for all
three subsets of peaks. C) De novo motif analysis reveals the same novel motif found in the SKBR3 cells underlying the binding sites in the BT474 cell
line. D) Venn diagrams comparing the binding sites found in the two breast cancer cell lines, SKBR3 and BT474, under asynchronous conditions (left)
and EGF treatment conditions (right). In asynchronous cells, the majority of the sites are independent, while after EGF treatment, the majority of
SKBR3 binding sites are also found in the BT474 cells.
https://doi.org/10.1371/journal.pone.0225180.g002
HER2 binding at the chromatin
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the BT474 cell line, 3,976 regions were co-occupied by HER2 and H3K4me1, representing
13.6% of all the HER2 bound regions in this specific cell line (S2C Fig). As such, a small pro-
portion of the HER2 bound regions are bona fide enhancer elements.
Genome-wide mapping of HER2 revealed thousands of regions of the genome occupied by
this receptor in two independent breast cancer cell lines. As previously shown (S1A Fig) chro-
matin fractionation followed by Western blotting confirmed HER2 chromatin occupancy. We
explored an additional independent method for assessing HER2-chromatin interactions, spe-
cifically proximity ligation assay (PLA). PLA permits sensitive identification of in situ protein-
protein interactions based on physical proximity [21]. We established a PLA assay to assess
interactions between HER2 and histone H3K4me1. In the first instance, we confirmed that
Fig 3. HER2 and H3K4me1 co-localise at the chromatin. HER2 and H3K4me1 co-localise at the chromatin near genes involved in signal transduction
and protein kinase activity. A) Venn diagram illustrating the overlapping sites of HER2 and H3K4me1 in the SKBR3 cells. Genes with common binding
sites within 10kb of the TSS were analysed using the Broad Institute’s GSEA website, revealing significant enrichment for Signal Transduction GO
pathways. B) Proximity ligation assay utilising antibodies raised against HER2 and H3K4me1 illustrating a reduction in the number of fluorescent foci
with knockdown using siRNA against HER2. Anti-HER2 (mouse monoclonal, Abcam ab16901) and anti-H3K4me1 (rabbit polyclonal, Abcam ab8895)
antibodies were used for PLA experiments. Histogram with quantification of fluorescent foci. �p-value< 0.05 (Student’s t-test). Inset: confirmation of
knockdown of HER2. C) Examples of fluorescent images generated from PLA. HER2-negative MDA-MB-231 cells were used as negative control cell
line. Additional controls included substituting the individual primary antibodies with IgG (bottom panel).
https://doi.org/10.1371/journal.pone.0225180.g003
HER2 binding at the chromatin
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EGF treatment increased the interaction of HER2 and H3K4me1 in comparison to control
cells (S2D Fig). Subsequently, we performed PLA in EGF-stimulated SKBR3 cell lines using
HER2 siRNA, which was effective at silencing the HER2 protein (Fig 3B). Interactions between
HER2 and H3K4me1 were observed using PLA and silencing of HER2 significantly reduced
the number of immunofluorescent foci observed in the nuclei of the EGF-treated breast cancer
cells (Fig 3B and 3C). MDA-MB-231, a cell line which does not express HER2, was used as a
negative control and did not show any signal from PLA experiments conducted between
HER2 and H3K4me1.
Genes within 10kb of the common HER2 and H3K4me1 binding sites revealed 222 genes
in SKBR3 cells and 2,123 genes in the BT474 cell line. Gene Set Enrichment Analysis [22, 23]
showed that both of these gene lists were enriched for Gene Ontology terms involving signal
transduction (Fig 3A). Included in the lists of genes were important signalling proteins such as
MAP3K13, PRKCH, Myc and MAPK11.
Proteomic analysis of HER2 binding partners at the chromatin reveals
interactions with STAT3 and EGFR
Having established the binding of HER2 to chromatin in two breast cancer cell lines, a modi-
fied rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) protocol
was used to identify partners of HER2 at the chromatin [24]. Two replicates were performed,
each using a different nuclear/chromatin preparation kit and the cells were labelled using sta-
ble isotope labelling by amino acids in cell culture (SILAC). Asynchronous SKBR3 cells were
grown in SILAC medium and treated with vehicle or EGF for 3 hours. Following HER2 purifi-
cation combined with MS analysis, HER2 was revealed as the top protein, validating the purifi-
cation approach and the antibody used for ChIP-exo. Peptide coverage of the HER2 protein is
shown in Fig 4A. EGFR, a known interactor of HER2 at the membrane was also found to inter-
act with HER2 at the chromatin (Table 1, S1 Table). Importantly, the transcription factor,
STAT3, was confirmed to interact with HER2, suggesting potential global functional interplay
between these two proteins, in support of the locus specific evidence linking these factors [8].
The interaction of HER2 with EGFR and STAT3 in the nucleus was confirmed by coimmuno-
precipitation in the SKBR3 cell line (S2D Fig).
Genomic binding of HER2 and H3K4me1 correlates with expression of
nearby genes
In order to test whether the HER2 genomic binding events had a functional impact, HER2
binding was coupled with gene expression in the SKBR3 cell line. The SKBR3 breast cancer
cell line was treated with vehicle or EGF for 3 hours and total RNA was collected for RNA-seq.
Five replicates were conducted. The comparison of these samples allowed us to determine
which genes were regulated by EGF expression. A total of 7,271 genes were differentially
regulated in SKBR3 cells by EGF treatment (FDR 0.01). In order to look at the effect of the
HER2 and H3K4me1 binding on these differentially regulated genes, we used two different
approaches. Specifically, we focused on genes that had both HER2 binding and H3K4me1 sig-
nal within the gene body or up to 10kb upstream from the transcription start site, resulting in
a total of 373 genes. A number of these genes were differentially expressed (59 upregulated,
314 downregulated) upon EGF treatment of the SKBR3 cell line, as illustrated by heatmap (Fig
4B). Gene set enrichment analysis revealed that HER2- and H3K4me1-occupied genes were
also the genes that were upregulated by EGF stimulation (Fig 4C), suggesting that the HER2
binding occurred at functional enhancer elements, as demarcated by H3K4me1 and that these
regions become transcriptional regulatory elements.
HER2 binding at the chromatin
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Fig 4. Mass spectrometry and RNAseq reveal STAT3 and EGFR as interacting partners at the chromatin. Mass spectrometry and RNAseq reveal
STAT3 and EGFR as interacting partners at the chromatin, with a subsequent influence on expression of nearby genes. A) Peptide coverage of HER2,
EGFR, STAT3 from the RIME data from SKBR3 cells. Green and yellow bars represent regions of the full-length protein sequence in which the peptides
were identified. Green indicates a high confidence (FDR<1%) peptide and yellow indicates a median confidence peptide (FDR<5%). B) Heatmap from
RNAseq in the SKBR3 cell line of the differentially expressed genes which have a HER2 and H3K4me1 overlapping binding site either within the gene
body or within 10kb upstream from the TSS. Fifty-nine genes were upregulated and 314 genes were downregulated. C) GSEA analysis combining genes
upregulated upon EGF treatment from RNAseq data with the overlapping HER2/H3K4me1 binding sites. A correlation between the ChIP peaks and
the upregulated genes in RNAseq is illustrated. Normalised Enrichment Score was 1.0976515.
https://doi.org/10.1371/journal.pone.0225180.g004
HER2 binding at the chromatin
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Discussion
The membrane receptor HER2 is a standard clinicopathological variable that is used to stratify
breast cancer patients onto specific treatment regimes. While the presence of this molecule
in the nucleus of cells has been noted in a handful of publications, this is the first time that
global analysis of HER2 binding has been reported. Analysis of the binding of HER2 was
achieved using the ChIP-exo method, which increases the sensitivity of ChIP based mapping
approaches. In this study we have profiled HER2 binding to the chromatin in two breast can-
cer cell lines with an amplified ErbB2 locus. In the SKBR3 cell line, binding was observed in
both asynchronous cells and following treatment with EGF. The majority of sites in EGF con-
ditions were new binding sites for HER2, indicating a re-programming of the binding in the
presence of EGF supplementation. In contrast, in the BT474 cell line, although EGF induced a
large number of new binding sites for HER2, the majority of the binding sites found in asyn-
chronous cells were also found in EGF-treated cells. Notably, the new sites induced by EGF
treatment did not have a high average intensity. Importantly, de novo motif analysis revealed a
novel motif underlying the peaks in both cell lines. Wang et al [11] reported a HER2-associated
sequence (HAS) of ‘TCAAATTTC’ in the promoter of the COX2 gene. This differs consider-
ably to the motif which we have identified in this study. However, we have analysed the
sequence which is bound by HER2 across hundreds of sites and in two different cell lines.
As EGF does not act as a direct ligand for HER2, this result could indicate that binding of
HER2 to the chromatin is linked to dimerization with EGFR. EGFR itself has previously been
reported to also localise to the nucleus in human squamous carcinoma and breast cancer cells
[25]. In support of this hypothesis, our proteomic purification analysis revealed an interaction
between HER2 and EGFR on the chromatin. Previous reports have identified a shorter variant
of ErbB3 interacting with the Cyclin D1 promoter region, and the full length ErbB3 interacting
with HER2 in the nucleus [17, 26]. In our study, we did not find an interaction between ErbB3
and HER2 in our mass spectrometry results but this may be due to stimulation with EGF
rather than Heregulin, the ligand for ErbB3. The majority of the HER2 binding sites found in
the EGF-treated SKBR3 cell line were also found in the BT474 cell line. There were over two
thousand common peaks found in both cell lines and these shared binding regions had the
highest signal intensity when compared to cell line specific HER2 binding sites, suggesting that
the co-occurring HER2 binding sites are the strongest chromatin binding sites and likely play
the most important functional role.
In order to gain confidence that the HER2 binding regions were functionally important,
we correlated our genome-wide binding information with H3K4me1 ChIP-seq data, since
H3K4me1 demarcates functional enhancer elements [20]. We found that approximately 16.4%
of the EGF induced HER2 peaks in SKBR3 cells overlapped with H3K4me1. Interestingly,
these common peaks of HER2 and H3K4me1 were found to be enhanced near genes classified
in ‘Signal Transduction’ functions, suggesting that HER2 might directly regulate transcription
of gene expression programmes that represent the same kinase signalling pathways that are
potentially activated by the membrane HER2 pathway.
Table 1. Mass spectrometry results from SKBR3 cells detailing the number of unique peptides detected for HER2,
STAT3 and EGFR.
JP602/HER2 IP JP603/IgG JP628/HER2 IP JP629/IgG
HER2 32 1 28 0
STAT3 6 1 10 0
EGFR 4 0 5 0
https://doi.org/10.1371/journal.pone.0225180.t001
HER2 binding at the chromatin
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Previous studies have reported HER2 and EGFR translocation to the nucleus involving the
integral trafficking from the endoplasmic reticulum to the nuclear envelope transport (INTER-
NET) pathway [7, 27]. This involves internalisation of the transmembrane receptor from the
cell surface by endocytosis, movement from the Golgi to the endoplasmic reticulum and trans-
location to the inner nuclear membrane. A number of proteins have been reported to be
involved in this process, including Importin β1, Nup358 and Sec61 [7, 27]. There is the possi-
bility that the INTERNET process is involved in translocating both HER2 and EGFR as a het-
erodimer to the nucleus. Interaction with HER2 and the transcription factor STAT3 was also
observed in our unbiased proteomic purification analysis and STAT3 has previously been
reported to localise with HER2 at the chromatin and may be a critical functional partner of
the complex, playing a direct role in gene regulation [8]. How chromatin bound HER2 con-
tributes to this gene regulation is unknown but it could possibly involve phosphorylation and
subsequent activation of partner proteins or histones. Members of the MAPK and JAK/STAT
pathways including JAK2 and JNK have previously been reported to phosphorylate histones
[28, 29].
Our work has complimented that of others in exploring the role of HER2 at the chromatin,
confirming that apart from the important canonical role of HER2 in signal transduction at the
membrane, there is another aspect to this receptor tyrosine kinase.
Conclusion
This study provides the first genome-wide binding analysis of the transmembrane receptor
HER2. We discovered over two thousand HER2 binding events that were common in two
independent breast cancer cell lines, and found colocalisation with the enhancer mark
H3K4me1. In addition, HER2 binding correlated with gene expression events induced by
EGF. Our understanding of the role of HER2 in breast cancer has mainly focused on the classic
view of HER2 as a transmembrane receptor integrated in the plasma membrane of the cell.
Our work and that of others have demonstrated that this simplified model is incomplete and
ignores the action of HER2 within the nucleus and on the chromatin. Further investigation is
required to determine the exact mechanism of HER2 activity within the nucleus.
Materials and methods
Cell lines and culturing
SKBR3 and BT474 human cell lines were obtained directly from American Type Culture Col-
lection. SKBR3 cells were grown in McCoys 5A Glutamax, supplemented with 10% FBS.
BT474 cells were grown in RPMI-1640, supplemented with 10% FBS. All cell lines were regu-
larly genotyped using STR profiling using the Promega GenePrint 10 system. Cell lines were
regularly tested for mycoplasma infection. Cells were treated, without any serum deprivation,
for 3 hours with vehicle (H2O) or EGF (100ng/ml, Sigma-Aldrich, St Louis, MO, USA).
ChIP-exo and ChIP-seq
ChIP-exo and ChIP-seq experiments were performed as previously described [18, 30]. In brief,
for ChIP-exo, formaldehyde cross-linked cells were lysed with a series of buffers to isolate the
chromatin which was then sonicated. The chromatin was added to antibody-bead complexes
and rotated at 4˚C overnight. Beads with antibody/protein/chomatin bound were washed in
RIPA buffer (50mM HEPES pH 7.6, 1mM EDTA, 0.7% Na deoxycholate, 1% NP-40, 0.5M
LiCL) six times, then twice in 10mM Tris HCl pH8.0. End repair, P7 adapter ligation and nick
repair were performed on the beads, followed by the Lambda and RecJf exonuclease reactions.
HER2 binding at the chromatin
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Chromatin bound to the antibody of choice was eluted/reverse crosslinked at 65˚C overnight.
A phenol:chloroform extraction was performed followed by second strand synthesis, P5
adapter ligation and PCR amplification. DNA of 200-350bp was selected and extracted from
an agarose gel. Antibodies used were anti-HER2 (Santa Cruz, sc-284, lots numbers F0512,
I2712, K0711, B1413) and anti-H3K4me1 (Abcam, ab8895, lot number GR149140-1). For each
ChIP-exo/seq experiment, 10 μg (HER2) or 5 μg (H3K4me1) of antibody was used.
ChIP-exo and ChIP-seq data analysis
Single-end 36 bp reads were generated on the Illumina Hi-Seq2500 and mapped to hg19
genome using bowtie2 2.2.6 [31]. Aligned reads with the mapping quality less than 5 were fil-
tered out. Peaks were called with MACS2 version 2.0.10.20131216 [19] for HER2 data and
Sicer version 1.1 [32] for the histone mark data. using sequences from the SKBR3 and BT474
chromatin extracts as a background input control. A further filtration was carried out by
removing reads falling into the ‘blacklist’ regions identified by ENCODE [33] or in regions
found to have high signals in cell-line-specific input samples as determined by the Bioconduc-
tor package GreyListChIP (http://www.bioconductor.org/packages/release/bioc/html/
GreyListChIP.html). The peaks yielded with MACS2 q value < = 1e-3 were selected for down-
stream analysis. Meme version 4.9.1 [34] was used to detect known and discover novel binding
motifs amongst tag-enriched sequences. The Broad Institute’s Gene Set Enrichment Analysis
(GSEA) website (http://software.broadinstitute.org/gsea) was used to perform Gene Ontology
studies.
Rapid IP-mass spectrometry of endogenous protein (RIME)
RIME experiments [24] were performed using two nuclear/chromatin extraction kits. Nuclei
Pure Prep Nuclei Isolation kit (Sigma, St Louis, MO, USA) and the chromatin fraction from the
Subcellular Extraction kit (Thermo Scientific, Rockford, IL, USA) were used for immunoprecip-
itating the protein complexes. SKBR3 cells were grown in R/K-deficient SILAC DMEM (PAA;
E15-086), 10% dialysed serum (Sigma-Aldrich; F0392), and supplemented with 800mM L-lysine
13C6
15N2 hydrochloride and 482mM L -arginine
13C6
15N4 hydrochloride (Sigma- Aldrich) for
‘heavy’-labelled media or 800mM L-lysine
12C6
14N2 hydrochloride and 482mM L-arginine
12C6
14N4 hydrochloride for ‘light’-labelled media. Antibody used was anti-HER2 (sc-284, Santa
Cruz, lot number B1413). Each RIME experiment was performed by mixing cells from each
label after respective drug treatments. One replicate was performed for each extraction kit,
with the SILAC labels switched between the treatments. Bead-bound proteins were digested
by the addition of 10 ml trypsin solution 15 ng /ul (Worthington Biochemicals) in 100mM
ammonium bicarbonate. The beads were then incubated at 37˚C overnight. A second step
digestion was performed the following day for 4 h. Sample tubes were placed on a magnetic
rack and the supernatant solution was collected and acidified by the addition of 2 ml 5%
formic acid. The samples were then cleaned using Ultra-Micro C18 Spin Columns (Harvard
Apparatus) prior to the mass spectrometry (MS) analysis according to manufacturer’s
instructions.
MS was performed using an LTQ Velos-Orbitrap MS (Thermo Scientific) coupled to an
Ultimate RSLCnano-LC system (Dionex). Optimal separation conditions resulting in maximal
peptide coverage were achieved using an Acclaim PepMap 100 column (C18, 3 μm, 100 Å)
(Dionex) with an internal diameter of 75 μm and capillary length of 25 cm. A flow rate of 350
nl/min was used with a solvent gradient of 5% B to 50% B in 120 min. Solvent A was 0.1%
(v/v) formic acid in water, whereas the composition of solvent B was 80% (v/v) acetonitrile in
0.1% (v/v) formic acid.
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The mass spectrometer was operated in positive ion mode using an Nth order double-play
method to automatically switch between Orbitrap-MS and LTQ Velos-MS/MS acquisition.
Survey full-scan MS spectra (from 400 to 1,600 m/z) were acquired in the Orbitrap with resolu-
tion (R) 60,000 at 400 m/z. The method allowed sequential isolation of the 10 most intense
ions for fragmentation in the linear ion trap, depending on signal intensity, using CID at colli-
sion energy 30. Target ions already selected for MS/MS were dynamically excluded for 20 s.
General MS conditions were electrospray voltage, 2.0kV with no sheath or auxiliary gas flow,
an ion selection threshold of 1,000 counts for MS/MS, an activation Q value of 0.25, activation
time of 10 ms and an S-Lens RF level of 65% were also applied.
RIME analysis
Raw MS data files were processed using Proteome Discoverer v.1.4 (Thermo Scientific). Pro-
cessed files were searched against the SwissProt human database using the Sequest HT. The
Nodes for SequestHT included the following parameters: Precursor Mass Tolerance 20ppm,
Fragment Mass Tolerance 0.5 Da, Dynamic Modifications were Oxidation of M (+15.995 Da)
and Deamidation of N, Q (+0.984 Da). Protein quantification was based on the relative precur-
sor intensity of the light and heavy R(10), K(8) SILAC labelled versions of their matching pep-
tides. The level of confidence for peptide identifications was estimated using the Percolator
node with decoy database search. FDR<1% was applied in all the runs.
Proximity ligation assay (PLA)
Cells were fixed and permeabilised by treating 5 minutes with methanol (-20˚C) and washing
thrice with cold phosphate buffered saline. PLA was carried out according to the supplier’s
protocol (Olink Bioscience). Primary antibodies used for the PLA reaction were anti-methyl
Histone H3 Lysine 4 at a 1/50 dilution (Abcam ab8895) and anti HER2 at a 1/75 dilution
(Abcam ab16901). Cells were observed with a Nikon Eclipse Ni-E microscope at magnification
x630 and images were captured with Nikon’s NIS Elements Imaging software. DAPI and PLA
fluorescence were captured at high resolution with automated 0.5μm z- sections for a total of 8
separate z-sections per observation field. All Z-sections were then stacked. Cell numeration
and PLA labeling were carried out using Image J software. Cells and red PLA dots were
counted using the ‘Analyze Particles’ function. For each condition, at least 200 cells were
imaged and analyzed. A mean value of number of spots per nucleus was then calculated and
normalised to the SKBR3 siNT sample. All statistical analyses were carried out by performing
student’s T-Test.
RNAseq
Total RNA was extracted from cells treated with vehicle or EGF (100ng/ml) for 3 hours. RNA-
seq libraries were prepared using Illumina’s TruSeq mRNA Stranded Sample prep kit. Five
replicates were performed for each treatment.
RNAseq data analysis
Single-end 40BP reads generated on the Illumina HiSeq were aligned to the human genome
version GRCh37.64 using TopHat version 2.0.4 [35]. Read counts were then obtained using
HTSeq-count version 0.5.3p9 (http://www-huber.embl.de/users/anders/HTSeq/doc/overview.
html). Read counts were then normalised and tested for differential gene expression using the
Bioconductor package DESeq2 [36] version 1.8.1. Multiple testing correction was applied
HER2 binding at the chromatin
PLOS ONE | https://doi.org/10.1371/journal.pone.0225180 November 20, 2019 12 / 17
using the Benjamini-Hochberg method. Genes were selected as differentially expressed such
that FDR <0.01.
Integration of RNAseq and ChIP-seq data
Chip-seq/exo binding sites were annotated using genomic features of the Human Genome
Assembly [GRCh37]. Genes whose body coordinates were in the proximity to chip-seq peak
summits within region of +/- 10kbp were selected as potential target genes for regulation by
HER2. P-values derived from DESeq2 analyses of the RNA-Seq data for all selected genes
were–log10 transformed. These values were subsequently used for ranking and weighting of
genes. GSEAPreranked analysis tool from Gene Set Enrichment Analysis (GSEA) software,
version 2.2.3 (http://software.broadinstitute.org/gsea/index.jsp) has been used for establishing
potential functional relation between Chip-seq/exo site location and gene expression. For hier-
archical clustering, RNA-seq read counts were normalised using library size and standard
deviation coefficients and then log2 transformed. Clustering functions and heatmap visualisa-
tion was performed using Matlab Bioinformatics toolbox framework (https://uk.mathworks.
com/products/bioinfo.html).
Western blot
Immunoblotting was performed using anti-ErbB2 (sc-284, Santa Cruz), anti-Tubulin (DM1a,
Sigma-Aldrich), anti-Lamin B (ab20396, Abcam), anti-phospho-ERK1/2 (4370, Cell Signal-
ling), anti-β-Actin (ab6276, Abcam).
In brief, whole cell lysates were extracted using the Pierce RIPA Buffer (Cat No 89900,
Thermo Fisher Scientific) and quantified using the Bradford assay.
Chromatin fractionations were performed as follows: Cells pellets were resuspended in
Buffer A [10mM Hepes (pH 7.9), 10mM KCl, 1.5mM MgCl2, 0.34M Sucrose, 10% glycerol]
with 1mM DTT, protease inhibitors (PI), 0.1mM PMSF, 0.1% Triton X-100 and incubated on
ice for 10 minutes. Nuclei were collected by centrifugation, 3,500rpm 5 minutes, 4˚C. Superna-
tant was retained as cytosolic fraction. The pellet was washed once in Buffer A (plus 1mM
DTT, PI, 0.1mM PMSF, no detergent) then resuspended in 200 μl of Buffer B [3mM EDTA,
0.2mM EGTA] with 1mM DTT, PI, 0.1mM PMSF and vortexed. Incubated on ice for 30 min-
utes with occasional vortexing, centrifuged at 4,000 rpm for 5 minutes at 4˚C. The supernatant
was retained as nucleoplasmic fraction. The pellet was wash pellet (x5) in 300 μl Buffer B (plus
1mM DTT, PI, 0.1mM PMSF). On last wash, sample was sonicated for 30 seconds then centri-
fuged at 5,000 rpm for 5 minutes at 4˚C. The pellet was resuspended in 55 μl 1X DNase I Buffer
(Ambion AM2222) plus 5 μl DNase and incubated at 37˚C for 30–60 minutes. A needle and
syringe were used to homogenise the sample if needed.
Samples were run on pre-cast NuPAGE™ 4–12% Bis-Tris Protein Gels (Thermo Fisher Sci-
entific) until fully separated by molecular weight then transferred to a nitrocellulose mem-
brane using iBlot1Gel Transfer Device (Thermo Fisher Scientific) before incubation with
blocking solution, following be primary and secondary antibodies. Proteins were detected
using standard chemiluminescence.
Data Deposition
The mass spectrometry proteomics data have been deposited to the ProteomeXchange
Consortium via the PRIDE partner repository with the dataset identifier PXD003915.
ChIPseq and RNAseq data have been deposited in the GEO database under the reference
GSE79778.
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Supporting information
S1 Fig. A) Western blot analysis using fractionated cell lysates from SKBR3 and BT474 cells,
under asynchronous and EGF-treatment conditions. Cells were treated for 3 hours with
100ng/ml EGF. B) Comparison of HER2 ChIPexo and ChIPseq UCSC genome browser shots,
illustrating the increased sensitivity of the ChIPexo method in detecting HER2 binding sites.
C) Western blot analysis of cell lysates from SKBR3 cells after EGF treatment. Induction of
pERK1/2 confirms the action of EGF in the treated cells. D) Venn diagram and UCSC genome
browser shots illustrating the unique and common peaks in asynchronous and EGF-treated
SKBR3 cells. E) CEAS analysis of the binding sites of HER2 in the SKBR3 cell line across vari-
ous features of the genome.
(TIF)
S2 Fig. A) Venn diagram and average intensity plots of HER2 ChIPexo binding sites in the
BT474 cell line. The binding sites found in both the asynchronous and EGF-treated cells had
the strongest average intensity. B) CEAS analysis of the binding sites of HER2 in the BT474
cell line across various features of the genome. C) Venn diagram illustrating the overlap
between HER2 binding sites with H3K4me1 under EGF conditions in the BT474 cell line. D)
Proximity ligation assay in the SKBR3 cell line utilising antibodies raised against HER2 and
H3K4me1 illustrating an increase in the number of fluorescent foci with treatment of the
EGF in comparison to control (PBS) treated cells. Anti-HER2 (mouse monoclonal, Abcam
ab16901) and anti-H3K4me1 (rabbit polyclonal, Abcam ab8895) antibodies were used for PLA
experiments. Histogram with quantification of fluorescent foci. �p-value < 0.05 (Student’s t-
test). E) Coimmunoprecipitation in the SKBR3 cell line. EGFR and STAT3 were immunopre-
cipitated and western blot performed for HER2.
(TIF)
S1 Table. HER2 RIME full data. Data from RIME experiments, from HER2 and IgG immu-
noprecipitations using nuclear and chromatin fractions from SKBR3 cell lines. In sample 602
& 603, EGF treated cells had been cultured in media containing heavy arginine and lysine, and
vehicle treated cells had been cultured in media containing light arginine & lysine. In samples
628 & 629, the labels were reversed, i.e. the EGF treated cells had been cultured in media con-
taining light arginine and lysine, and vehicle treated cells had been cultured in media contain-
ing heavy arginine & lysine.
(XLSX)
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